Patents by Inventor James Wassenberg

James Wassenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoassay for detecting Zika virus infection
    Patent number: 11604192
    Abstract: A biological sample, for example blood, serum, or plasma, is evaluated for the presence of anti-Zika virus (ZIKV) IgM- and IgG antibodies specific for ZIKV nonstructural protein 1 (NS1) by measuring the signal intensities of such antibodies in an immunoassay of the sample. Subjects are scored as being positive or negative for ZIKV infection based on the combined results of such determinations.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: March 14, 2023
    Assignee: DiaSorin Italia S.p.A.
    Inventors: Fabrizio Bonelli, Tina Bunnell, James Wassenberg
  • Immunoassay for Detecting Zika Virus Infection
    Publication number: 20230072761
    Abstract: The present invention relates to a method for detecting Zika vims (ZIKV) infection in a biological sample from a subject. The method comprises testing the sample for IgM- and IgG-ZIKV NSI antibodies and determining the ZIKV IgM and ZIKV IgG signal intensities; and scoring the sample as positive or negative for ZIKV infection based on the combined results of such determinations. The biological sample is preferably blood, serum, plasma, cerebrospinal fluid, saliva or urine.
    Type: Application
    Filed: November 7, 2022
    Publication date: March 9, 2023
    Applicant: DiaSorin Italia S.p.A.
    Inventors: Fabrizio Bonelli, Tina Bunnell, James Wassenberg
  • Immunoassay for Detecting Zika Virus Infection
    Publication number: 20200025760
    Abstract: The present invention relates to a method for detecting Zika virus (ZIKV) infection in a biological sample from a subject. The method comprises testing the sample for IgM- and IgG-ZIKV NS1 antibodies and determining the ZIKV IgM and ZIKV IgG signal intensities; and scoring the sample as positive or negative for ZIKV infection based on the combined results of such determinations. The biological sample is preferably blood, serum, plasma, cerebrospinal fluid, saliva or urine.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 23, 2020
    Applicant: DiaSorin S.p.A.
    Inventors: Fabrizio Bonelli, Tina Bunnell, James Wassenberg